<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Jain, Manish</dc:creator>
  <dc:creator>Zellweger, Matthieu</dc:creator>
  <dc:creator>Wagnières, Georges</dc:creator>
  <dc:creator>Bergh, Hubert van den</dc:creator>
  <dc:creator>Cook, Stéphane</dc:creator>
  <dc:creator>Giraud, Marie-Noëlle</dc:creator>
  <dc:date>2017-04-01</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Acute coronary syndrome is a life-threatening condition of utmost clinical importance,  which, despite recent progress in the field, is still associated with high morbidity and  mortality. Acute coronary syndrome results from a rupture or erosion of vulnerable  atherosclerotic plaque with secondary platelet activation and thrombus formation,  which leads to partial or complete luminal obstruction of a coronary artery. During the  last decade, scientific evidence demonstrated that when an acute coronary event  occurs, several nonculprit plaques are in a “vulnerable” state. Among the promising  approaches, several investigations provided evidence of photodynamic therapy  (PDT)-induced stabilization and regression of atherosclerotic plaque. Significant  development of PDT strategies improved its therapeutic outcome. This review  addresses PDT's pertinence and major problems/challenges toward its translation to a  clinical reality.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/305624</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/305624/files/gir_ptt.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/1755-5922.12238</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Cardiovascular Therapeutics. - 2017, vol. 35, no. 2, p. e12238</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Atherosclerosis</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Laser</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Photodynamic therapy</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Photosensitizers</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Restenosis</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Theranostic</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns7="xml" ns7:lang="en">Photodynamic therapy for the treatment of atherosclerotic plaque: Lost in translation?</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
